SCHEMBL10163598

SCHEMBL10163598

Cn1c(=O)oc2ccc(CNC(=O)c3cc(C(=O)NCc4ccc(C(C)(F)F)nc4)n4nccc4n3)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.36
MMP3 P08254 1/20 0.36
MMP8 P22894 1/20 0.36
MMP12 P39900 1/20 0.36
MMP13 P45452 1/20 0.36
LMNA P02545 2/20 0.35
KMT2A Q03164 4/20 0.34
NAMPT P43490 1/20 0.34
TP53 P04637 1/20 0.34
PIK3CA P42336 1/20 0.34
GLS O94925 1/20 0.34
GLA P06280 1/20 0.34
METTL3 Q86U44 2/20 0.34
METTL14 Q9HCE5 2/20 0.34
MAPT P10636 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13161853 0.94 GLS (0.40) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL10163587 0.89 MMP13 (0.37) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL10163535 0.89 MMP13 (0.42) ADAMTS4MMP3MMP13LMNAKMT2A
SCHEMBL10163558 0.89 GLS (0.37) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL8226340 0.88 MMP13 (0.37) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL8227563 0.87 CDK2 (0.37) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL8225958 0.86 TP53 (0.44) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL10162868 0.86 KCNN3 (0.37) ADAMTS4MMP3MMP8MMP12MMP13
SCHEMBL8228682 0.85 MMP13 (0.47) MMP13LMNAPIK3CAGLAMAPT
SCHEMBL8229564 0.85 CACNA1G (0.43) ADAMTS4MMP3MMP8MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP8 26/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP8 26/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ADAMTS4 38/4885MMP3 3/4885MMP8 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.